0001179110-16-032838.txt : 20161212
0001179110-16-032838.hdr.sgml : 20161212
20161212184338
ACCESSION NUMBER: 0001179110-16-032838
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161208
FILED AS OF DATE: 20161212
DATE AS OF CHANGE: 20161212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001061027
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943295878
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 OYSTER POINT BOULEVARD
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-266-3500
MAIL ADDRESS:
STREET 1: 395 OYSTER POINT BOULEVARD
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19980709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Parker Geoffrey M.
CENTRAL INDEX KEY: 0001491874
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51531
FILM NUMBER: 162047314
MAIL ADDRESS:
STREET 1: 15 RIORDAN PLACE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
edgar.xml
FORM 4 -
X0306
4
2016-12-08
0
0001061027
SUNESIS PHARMACEUTICALS INC
SNSS
0001491874
Parker Geoffrey M.
395 OYSTER POINT BLVD.
SUITE 400
SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2016-12-08
4
P
0
3146
3.865
A
65151
D
Common Stock
2016-12-09
4
P
0
594
3.9018
A
65745
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.80 to $3.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.79 to $3.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) of this Form 4.
/s/ Eric Bjerkholt (Attorney-in-Fact)
2016-12-12